Education
About Us
Working with TipRanks
Follow Us
Jazz Pharmaceuticals (JAZZ)
NASDAQ:JAZZ
JAZZ Analyst Ratings
Strong Buy
14 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
JAZZ Stock 12 Month Forecast
Average Price Target
$211.60
▲(28.30% Upside)
| Highest Price Target$247.00 | Average Price Target$211.60 | Lowest Price Target$173.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Piper Sandler
$147→$219
Buy
32.79%
Upside
Reiterated
12/10/25
UBS
$188
Hold
13.99%
Upside
Downgraded
11/24/25
Hold Rating for Jazz Pharmaceuticals Amid Balanced Risk-Reward and Competitive ChallengesZiihera GEA success uplifts financial profile, but priced in at current valuation We downgrade JAZZ to a Neutral rating, but increase our PT to $188 (from $163) . After a highly successful Ph3 Gastro esophageal adenocarcinoma (GEA) study update, the stock is up 25% as a reaction. At current valuation, we see JAZZ is fairly valued with balanced risk/ reward. Positive GEA study significantly uplifts the financial profile of the company; we now model '26-'29E Revenue/ EPS CAGR of 8%/8% (vs prior 5%/3%) vs cons 7%/10% . While there is likely to be continued positive sentiment on the story due to recent Oncology wins, we believe this is currently priced in to the stock valuation . With no significant upcoming catalysts, we see limited upside/downside.
Truist Financial
$205→$220
Buy
33.40%
Upside
Reiterated
11/19/25
Strong Buy Rating for Jazz Pharmaceuticals Driven by Promising Ziihera Drug and Positive Market OutlookWe are particularly encouraged by topline results showing efficacy in PD-L1- subgroup, which differentiates Ziihera in GEA (Exhibit 3). Given breadth of cancers that over-express HER2 for which Herceptin and Enhertu are SoC (Exhibit 2), we see a pipeline in a drug-like potential for Ziihera.
Wells Fargo
$170→$235
Buy
42.49%
Upside
Reiterated
11/18/25
Robert W. Baird
$160→$209
Buy
26.73%
Upside
Reiterated
11/18/25
Needham
$210
Buy
27.33%
Upside
Reiterated
11/17/25
Promising HERIZON-GEA Trial Results Drive Buy Rating for Jazz Pharmaceuticals' ZiiheraWe expect JAZZ to trade up meaningfully today following announcement of very positive results (LINK) from the HERIZON-GEA trial, as these results are even better than the upside scenario we highlighted in our preview note (LINK). Ziihera + chemotherapy delivered a statistically significant PFS benefit and a strong positive trend in OS versus the control arm, supporting an sNDA submission in 1H26. The Ziihera + tislelizumab + chemotherapy arm showed statistically significant improvements in both PFS and OS, in PD-L1–positive as well as PD-L1-negative subgroups, results that, in our view, strongly position Ziihera- based regimens to become the new standard of care in first-line HER2+ locally advanced unresectable or metastatic GEA. The next interim OS analysis for the Ziihera + chemo arm is expected in mid-2026.
Bank of America Securities
$230→$247
Buy
49.77%
Upside
Reiterated
11/17/25
Jazz Pharmaceuticals' Promising Pipeline and Strong Trial Results Lead to Buy Rating and Raised Price ObjectiveWe see today’s update as thesis- validating: 1) low multiple cannot hold forever once pipeline delivers and Ziihera is more de-risked $1bn+ peak, 2) underlying growth profile remains under-appreciated — see competitors bidding for alternative oxybate when considering durability of JAZZ’s Xywav franchise. We reiterate our Buy on JAZZ based on undemanding valuation & underappreciated growth; raise our PO to $247 (from $230) on higher EV/EBITDA (9x vs 8.5x previously) on positive GEA update.
RBC Capital
$155→$194
Buy
17.63%
Upside
Reiterated
11/17/25
Morgan Stanley
$185→$205
Buy
24.30%
Upside
Reiterated
11/17/25
Stifel Nicolaus
$230
Buy
39.46%
Upside
Reiterated
11/06/25
TD Cowen
$205
Buy
24.30%
Upside
Reiterated
11/06/25
J.P. Morgan
$204→$199
Buy
20.66%
Upside
Reiterated
10/27/25
Leerink Partners
$220→$215
Buy
30.37%
Upside
Reiterated
10/07/25
Deutsche Bank
$170→$173
Buy
4.90%
Upside
Reiterated
10/03/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Piper Sandler
$147→$219
Buy
32.79%
Upside
Reiterated
12/10/25
UBS
$188
Hold
13.99%
Upside
Downgraded
11/24/25
Hold Rating for Jazz Pharmaceuticals Amid Balanced Risk-Reward and Competitive ChallengesZiihera GEA success uplifts financial profile, but priced in at current valuation We downgrade JAZZ to a Neutral rating, but increase our PT to $188 (from $163) . After a highly successful Ph3 Gastro esophageal adenocarcinoma (GEA) study update, the stock is up 25% as a reaction. At current valuation, we see JAZZ is fairly valued with balanced risk/ reward. Positive GEA study significantly uplifts the financial profile of the company; we now model '26-'29E Revenue/ EPS CAGR of 8%/8% (vs prior 5%/3%) vs cons 7%/10% . While there is likely to be continued positive sentiment on the story due to recent Oncology wins, we believe this is currently priced in to the stock valuation . With no significant upcoming catalysts, we see limited upside/downside.
Truist Financial
$205→$220
Buy
33.40%
Upside
Reiterated
11/19/25
Strong Buy Rating for Jazz Pharmaceuticals Driven by Promising Ziihera Drug and Positive Market OutlookWe are particularly encouraged by topline results showing efficacy in PD-L1- subgroup, which differentiates Ziihera in GEA (Exhibit 3). Given breadth of cancers that over-express HER2 for which Herceptin and Enhertu are SoC (Exhibit 2), we see a pipeline in a drug-like potential for Ziihera.
Wells Fargo
$170→$235
Buy
42.49%
Upside
Reiterated
11/18/25
Robert W. Baird
$160→$209
Buy
26.73%
Upside
Reiterated
11/18/25
Needham
$210
Buy
27.33%
Upside
Reiterated
11/17/25
Promising HERIZON-GEA Trial Results Drive Buy Rating for Jazz Pharmaceuticals' ZiiheraWe expect JAZZ to trade up meaningfully today following announcement of very positive results (LINK) from the HERIZON-GEA trial, as these results are even better than the upside scenario we highlighted in our preview note (LINK). Ziihera + chemotherapy delivered a statistically significant PFS benefit and a strong positive trend in OS versus the control arm, supporting an sNDA submission in 1H26. The Ziihera + tislelizumab + chemotherapy arm showed statistically significant improvements in both PFS and OS, in PD-L1–positive as well as PD-L1-negative subgroups, results that, in our view, strongly position Ziihera- based regimens to become the new standard of care in first-line HER2+ locally advanced unresectable or metastatic GEA. The next interim OS analysis for the Ziihera + chemo arm is expected in mid-2026.
Bank of America Securities
$230→$247
Buy
49.77%
Upside
Reiterated
11/17/25
Jazz Pharmaceuticals' Promising Pipeline and Strong Trial Results Lead to Buy Rating and Raised Price ObjectiveWe see today’s update as thesis- validating: 1) low multiple cannot hold forever once pipeline delivers and Ziihera is more de-risked $1bn+ peak, 2) underlying growth profile remains under-appreciated — see competitors bidding for alternative oxybate when considering durability of JAZZ’s Xywav franchise. We reiterate our Buy on JAZZ based on undemanding valuation & underappreciated growth; raise our PO to $247 (from $230) on higher EV/EBITDA (9x vs 8.5x previously) on positive GEA update.
RBC Capital
$155→$194
Buy
17.63%
Upside
Reiterated
11/17/25
Morgan Stanley
$185→$205
Buy
24.30%
Upside
Reiterated
11/17/25
Stifel Nicolaus
$230
Buy
39.46%
Upside
Reiterated
11/06/25
TD Cowen
$205
Buy
24.30%
Upside
Reiterated
11/06/25
J.P. Morgan
$204→$199
Buy
20.66%
Upside
Reiterated
10/27/25
Leerink Partners
$220→$215
Buy
30.37%
Upside
Reiterated
10/07/25
Deutsche Bank
$170→$173
Buy
4.90%
Upside
Reiterated
10/03/25
Best Analysts Covering Jazz Pharmaceuticals
1 Month
xxx
Success Rate
27/43 ratings generated profit
Average Return
+1.40%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 62.79% of your transactions generating a profit, with an average return of +1.40% per trade.
3 Months
xxx
Success Rate
22/34 ratings generated profit
Average Return
+2.39%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 64.71% of your transactions generating a profit, with an average return of +2.39% per trade.
1 Year
2 Years
xxx
Success Rate
17/19 ratings generated profit
Average Return
+29.44%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 89.47% of your transactions generating a profit, with an average return of +29.44% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
JAZZ Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
24
17
19
9
9
Buy
22
17
17
21
20
Hold
5
4
5
5
6
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
51
38
41
35
35
Each month's total comprises the sum of three months' worth of ratings.
JAZZ Financial Forecast
JAZZ Stock Forecast FAQ
What is JAZZ’s average 12-month price target, according to analysts?
Based on analyst ratings, Jazz Pharmaceuticals’s 12-month average price target is 211.60.
What is JAZZ’s upside potential, based on the analysts’ average price target?
Jazz Pharmaceuticals has 28.30% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is JAZZ a Buy, Sell or Hold?
Jazz Pharmaceuticals has a consensus rating of Strong Buy which is based on 14 buy ratings, 1 hold ratings and 0 sell ratings.
What is Jazz Pharmaceuticals’s price target?
The average price target for Jazz Pharmaceuticals is 211.60. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $247.00 ,the lowest forecast is $173.00. The average price target represents 28.30% Increase from the current price of $164.92.
The highest analyst price target is $247.00 ,the lowest forecast is $173.00. The average price target represents 28.30% Increase from the current price of $164.92.
What do analysts say about Jazz Pharmaceuticals?
Jazz Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.
How can I buy shares of JAZZ?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.